Investment
Features
FeesSafety
Academy
More
Pluang+

Compare The Coca-Cola Co K (KO) vs Viatris Inc (VTRS) Price & Performance

The Coca-Cola Co KTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

The Coca-Cola Co K vs Viatris Inc — how do they compare? The Coca-Cola Co K trades at $86.51 (market cap $373.76B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: The Coca-Cola Co K is far larger — about 20× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

KOVTRS
Market Cap
$373.76B$18.69B
Volume
14,630,257
Sector
Consumer StaplesHealth
52-Week High
$89.08$17.86
52-Week Low
$65.67$9.49
Enterprise Value
$400.93B$30.81B
Dividend Yield
2.44%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

The Coca-Cola Co K

Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.

The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.

Viatris Inc

Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.

While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS